Clinical PerformanceTYRA-300 led to an impressive 55% ORR in FGFR3+ mUC patients dosed with >90mg, which is significantly higher than erda's ~35% ORR.
Ease Of UseAn oral therapy like TYRA-300 could reduce the need for regular hospital visits, making it a more appealing option for NMIBC patients seeking effective treatments with minimal disruption to their daily lives.
Market PotentialThere may be an important economic incentive for community urologists to prescribe TYRA-300, as TYRA-300 may be prescribed through a popular group purchasing organization, called UroGPO.